Sections

Weather Forecast

Close
Advertisement

U.S. contract approved to speed tests of Mapp's Ebola drug

Email News Alerts

Sept 2 (Reuters) - The U.S. Department of Health and Human Services said on Tuesday a federal contract worth up to $42.3 million would help accelerate testing of an experimental Ebola virus treatment that is being developed by privately held Mapp Biopharmaceutical Inc.

Advertisement

Get the full story
Subscribe or Log In

Are you a newspaper subscriber but you don't have a Digital Access account yet? Activate your account.

You will need your subscription account number and phone number. Not sure if you have an account? Call 218-855-5897 and we can help you.

Advertisement
Advertisement
randomness